Anti-viral treatment in patients with virus-induced cardiomyopathy.
Ongoing viral persistence in the myocardium is associated with an adverse prognosis of cardiomyopathy eventually resulting in a reduced capacity for work and thus it is associated with enormous social costs. Experimental and clinical data highlight that an imbalance of the cytokine network and a defect in the cytokine-induced immune response may constitute major causes leading to the development of virus persistence and progression of myocardial dysfunction. Reversibility of cardiac impairment during the early stages of the disease and the arising chance of specific treatment options demand early diagnosis and treatment of the disease. Our pilot data on anti-viral treatment using INF-beta showed beneficial clinical effects and suggest that some of the ventricular dysfunction and wall motion abnormalities resolved after elimination of the responsible agents. The data also suggest that elimination of cardiotropic viruses and associated clinical effects may occur even in DCM patients presenting with a long history.
Kühl
U
U
Department of Cardiology and Pneumology, Campus Benjamin Franklin, Charité University Medicine Berlin, Germany. uwe.kuehl@charite.de
Pauschinger
M
M
Poller
W
W
Schultheiss
H P
HP
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000188:drug therapy / Q000821:virology; D006321:Heart / Q000821:virology; D006801:Humans; D007109:Immunity / Q000502:physiology; D007155:Immunologic Factors / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D009206:Myocardium / Q000166:cytology / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000628:therapy / Q000821:virology; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology
D000998:Antiviral Agents; D007155:Immunologic Factors; D007372:Interferons